Levosimendan NEW
| Price | $61 | $237 |
| Package | 100mg | 500mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Levosimendan | CAS No.: 141505-33-1 |
| Purity: 99.44% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Levosimendan |
| Description | Levosimendan (OR1259) is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan exerts its effect by increasing calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner. |
| In vitro | Levosimendan caused contraction and relaxation of failing human cardiomyocytes, with a mean maximum increase in twitch tension of 47% at 0.8 μM Levosimendan.Levosimendan induced a rapid dose-dependent increase in hemodynamic functions in patients with compensated heart failure.Levosimendan caused a significant hyperpolarization (EPS) of resting potential (EPS) in rat mesenteric artery myocytes. The resting potential of rat mesenteric artery myocytes was markedly hyperpolarized by Levosimendan (EC50: 2.9 μM), with a maximal effect at 10 μM (19.5 mV), which may be produced by activation of glibenclamide-sensitive K+ channels.Levosimendan (3 μM) reduced the Ca50 from 2.73 μM to 1.19 μM. |
| In vivo | Levosimendan caused contraction and relaxation of failing human cardiomyocytes, with a mean maximum increase in twitch tension of 47% at 0.8 μM Levosimendan.Levosimendan induced a rapid dose-dependent increase in hemodynamic functions in patients with compensated heart failure.Levosimendan caused a significant hyperpolarization (EPS) of resting potential (EPS) in rat mesenteric artery myocytes. The resting potential of rat mesenteric artery myocytes was markedly hyperpolarized by Levosimendan (EC50: 2.9 μM), with a maximal effect at 10 μM (19.5 mV), which may be produced by activation of glibenclamide-sensitive K+ channels.Levosimendan (3 μM) reduced the Ca50 from 2.73 μM to 1.19 μM. |
| Storage | Keep away from direct sunlight Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 250 mg/mL (891.97 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.14 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | Simsndan | PotassiumChannel | Potassium Channel | Phosphodiesterase (PDE) | phosphodiesterase | OR-1855 | OR-1259 | OR 1855 | OR 1259 | Levosimendan | KcsA | Inhibitor | inhibit | Cardiac troponin C | CarbonicAnhydrase | Carbonic Anhydrase | Autophagy |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Urea | Tamoxifen | Sodium Dihydrogen Phosphate | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Hydroxychloroquine | Paeonol | Naringin | Alginic acid |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1000.00 |
VIP1Y
|
Chengdu Shengnuo Biopharm Co.,Ltd
|
2026-05-28 | |
|
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-05-20 | ||
| $5.00 |
Wuhan JiyunZen Tech Co., Ltd.
|
2026-04-10 | ||
| $10.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
|
Shanghai Affida new material science and technology center
|
2025-01-06 | |||
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-13 | ||
| $200.00 |
Longyan Tianhua Biological Technology Co., Ltd
|
2020-11-16 | ||
| $2.00 |
VIP8Y
|
Career Henan Chemical Co
|
2019-07-06 | |
|
Shanghai Affida new material science and technology center
|
2025-01-06 | |||
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY